Reduced risk of rheumatoid arthritis in patients with T2DM

(HealthDay) – Patients with type 2 diabetes mellitus (T2DM) have a reduced risk of rheumatoid arthritis (RA), which may be due to statin use, according to a study published online on February 16 in Rheumatology.

Dawit T. Zemedikun, from the University of Birmingham in the UK, and his colleagues conducted a retrospective cohort study to compare the risk of RA and investigate the role of glycemic control in the risk of RA. A total of 224,551 newly diagnosed patients with T2DM matched 449,101 patients without T2DM and were monitored to assess the risk of RA.

The researchers found that the incidence rate for RA was 8.1 and 10.6 per 10,000 person-years, respectively, in exposed and unexposed groups, during the study period (adjusted hazard ratio, 0.73; 95 percent confidence interval, 0, 67 to 0.79). The adjusted risk ratio was 0.89 (95 percent confidence interval, 0.69 to 1.14) in patients who did not use statins during their lifetime. In quantifying the effects of glycemic control, antidiabetic drugs, and statins, no significant associations were observed to glycemic control, metformin use, and dipeptidyl peptidase-4 inhibitors with the development of RA. However, among those with T2DM, a protective effect was observed for statins with RA progression (adjusted risk ratio 0.76; 95 percent confidence interval, 0.66 to 0.88), with evidence of a duration-response relationship.

“The results suggest that statin use may be associated with a reduced risk of RA, a finding that should be further investigated in a trial setting,” the authors write.

T2DM remission rates are higher in RYGB versus sleeve gastrectomy

More information:
Summary / Full text (subscription or payment may be required)

Copyright © 2020 HealthDay. All rights reserved.

Citation: Reduced risk for rheumatoid arthritis in patients with T2DM (2021, February 23) retrieved February 23, 2021 from

This document is protected by copyright. Except for any fair dealing for the purpose of private study or research, no part may be reproduced without written permission. The content is available for informational purposes only.